Morphine Drip Administration Guidelines
Initial Assessment and Route Selection
- Intravenous morphine is indicated for severe pain requiring rapid titration, particularly in patients unable to take oral medications or those with pain intensity NRS ≥5, as recommended by the European Society for Medical Oncology 1, 2
- The IV route achieves peak effects within 15-30 minutes, making it superior to oral administration for rapid pain control, according to the American Society of Clinical Oncology 3
Starting Doses for IV Morphine
- For severe cancer pain requiring rapid titration, a dose of 1.5 mg IV bolus every 10 minutes until pain relief or adverse effects occur is recommended by the European Society for Medical Oncology 1, 2
- The median dose to achieve pain relief with this protocol is 4.5 mg (range 1.5-34.5 mg), as reported by the European Society for Medical Oncology 1, 2
Continuous Infusion Protocol
- After initial bolus titration, convert to continuous infusion by calculating the total IV morphine required in the first 24 hours, as recommended by the European Society for Medical Oncology 1, 2
- Provide breakthrough doses equal to 10-15% of the total daily dose, available every 15-30 minutes for IV administration, according to the European Society for Medical Oncology 1, 2
Titration and Dose Adjustment
- Review total morphine consumption (basal infusion plus breakthrough doses) every 24 hours, as recommended by the National Comprehensive Cancer Network 6
- If more than 4 breakthrough doses are needed per day, increase the baseline infusion rate, according to the European Society for Medical Oncology 1, 2
Dose Modifications
- In renal impairment (eGFR <30 mL/min), start with lower doses and titrate slowly—morphine metabolites accumulate and cause toxicity, as recommended by the European Society for Medical Oncology 1, 2, 4
Concurrent Medications
- Prescribe laxatives routinely for prophylaxis of opioid-induced constipation, as recommended by the European Society for Medical Oncology 4
- Prescribe antiemetics (metoclopramide or antidopaminergics) for opioid-related nausea/vomiting, according to the European Society for Medical Oncology 4